In twenty years of treating the upper face, ptosis remains the complication I see practitioners worry about most, and with good reason. A drooping brow or heavy eyelid is visible immediately, and it tests your clinical confidence in a way that few other complications do. But eyebrow ptosis and lid ptosis are not the same condition. They involve different muscles, present differently, and require different management. Getting the distinction right determines how you respond.
This is one of the topics delegates raise most frequently during training. Here is what you need to know, drawn from the evidence and from what I have observed across thousands of consultations.
Key Takeaways
- Eyebrow ptosis involves the frontalis muscle; lid ptosis involves the levator palpebrae superioris – each requires a different management approach.
- Ptosis incidence drops below 1% with experienced injectors, compared with 5.4% in early FDA trials (King, J Clin Aesthet Dermatol, 2016).
- Lid ptosis responds to apraclonidine 0.5% eye drops (1–2 mm lid elevation); eyebrow ptosis may require a compensatory toxin injection.
- Maintaining injection points at least 1–2 cm above the brow line is the single most effective prevention measure.
What Is the Difference Between Eyebrow Ptosis and Lid Ptosis?
The distinction is anatomical. Eyebrow ptosis results from toxin affecting the frontalis – the muscle that elevates the brow. Lid ptosis involves the levator palpebrae superioris, the muscle responsible for opening the upper eyelid. A 2022 systematic review in the Aesthetic Surgery Journal reported an overall adverse event rate of 16% across 4,268 upper face toxin sessions (Zargaran et al., 2022). True ptosis, however, occurs in fewer than 1% of cases with experienced injectors (King, J Clin Aesthet Dermatol, 2016).
A 2025 UK survey of 919 patients paints a more concerning picture at the population level: 7.3% reported acute eyelid drooping after treatment, and 1.7% experienced persistent ptosis. Crucially, 22.5% of those treatments had been performed by beauticians and 28% by non-prescribers (Smith et al., ASJ Open Forum, 2025). When treatment is delivered by properly trained practitioners, the incidence drops dramatically. That gap is not a coincidence.
Why does this matter in practice? Because the management for each is entirely different. Apraclonidine eye drops work on Müller’s muscle in the eyelid. They have no effect on the frontalis. I have seen practitioners prescribe drops for what is clearly a brow problem, simply because they had not made the anatomical distinction. That is a knowledge gap, not a clinical failing – and it is precisely the sort of thing that thorough training prevents.
| Feature | Eyebrow Ptosis | Lid Ptosis |
|---|---|---|
| Muscle affected | Frontalis | Levator palpebrae superioris |
| Mechanism | Over-treatment or spread into frontalis reduces brow elevation | Toxin diffuses into the levator, weakening eyelid lift |
| Typical onset | 3–7 days post-treatment | 3–7 days post-treatment |
| Resolution | ~6 weeks | 3–4 weeks |
| Primary treatment | Compensatory toxin injection or wait | Apraclonidine 0.5% eye drops |
What Causes Eyebrow Ptosis After Anti-Wrinkle Treatment?
Eyebrow ptosis occurs when toxin migrates into – or overtreats – the frontalis, the muscle responsible for lifting the brow. Reported incidence ranges from under 1% with experienced practitioners to 5.4% in Allergan’s original FDA multicenter study of 263 patients (King, J Clin Aesthet Dermatol, 2016). What accounts for that gap? Technique.
Two factors explain most cases. First, over-dosing the frontalis in patients who rely heavily on frontalis recruitment to compensate for existing brow heaviness or dermatochalasis. Second, placement. Injecting too low on the forehead – close to or below the eyebrow – weakens the frontalis at the point where brow elevation matters most.
A dental background is relevant here. Dentistry trains you to think structurally about the face – bone, muscle insertions, tissue planes. When I assess a patient’s upper face before treatment, I apply the same biomechanical thinking I learnt at dental school to a different clinical question. That structural perspective makes it easier to identify higher-risk patients before you pick up a syringe.
Roughly 90% of patients have some degree of pre-existing brow asymmetry (King, 2016). If you do not assess this before treatment, even technically sound injections can produce apparent unilateral brow ptosis. In reality, you have unmasked an asymmetry that the frontalis was previously compensating for. I see this regularly and it is one of the first things I teach delegates to check.
Recognising and Managing Eyebrow Ptosis
The presentation is a heavy, drooping brow – typically appearing 3–7 days after treatment. Patients often describe their forehead feeling weighed down. Most cases resolve within approximately 6 weeks as the toxin effect diminishes (King, J Clin Aesthet Dermatol, 2016).
Will every case need intervention? No, mild brow ptosis often resolves on its own. The decision depends on severity and how distressed the patient is. For moderate to severe cases, a compensatory technique can help: a small intradermal toxin injection of approximately 2 units, placed 2–3 mm below the lateral brow, produces 1–2 mm of elevation by weakening the orbicularis pull at that point (King, 2016).
This is not intuitive. You are using more toxin to correct a toxin complication. But the principle makes sense, you are rebalancing the forces acting on the brow, not repeating the original error. Understanding the push-pull relationship between frontalis and orbicularis is essential.
What matters most is honest communication. Explain the timeline clearly to your patient. Six weeks feels considerably longer when you are the one living with a heavy brow.
What Causes Lid Ptosis After Anti-Wrinkle Treatment?
Lid ptosis occurs when toxin diffuses into the levator palpebrae superioris – the muscle that lifts the upper eyelid. Sethi et al. found eyelid ptosis in just 0.71% of treatments when proper technique was followed (Sethi et al., Aesthetic Plastic Surgery, 2021). That is reassuringly low – but understanding the mechanism is the key to keeping it there.
How does toxin reach the levator? Rarely from a direct eyelid injection. More typically, it diffuses from a nearby glabellar injection placed too close to the orbital rim, or injected at excessive volume in dilute solution. A 2024 meta-analysis of 20 randomised controlled trials found glabellar injections carried a relative risk of 5.56 for eyelid ptosis compared with placebo (Zhang et al., Aesthetic Plastic Surgery, 2025). At standard dilution, each injection point creates a halo of action of approximately 1.5 cm (King, 2016). That is a wide zone of effect when you are working millimetres from the orbit.
One thing I always assess is periorbital tissue quality. The orbital septum is not uniformly thick, and it becomes thinner with age. Patients with thin periorbital tissue have a lower threshold for toxin diffusion. This practical anatomical consideration does not feature prominently in most injection guides, but it matters clinically and should inform your dosing decisions.
How Do You Manage Lid Ptosis?
The hallmark is a visible droop of one or both upper eyelids, often with a reduced margin reflex distance below the normal 2.5 mm threshold. Patients may report looking tired, headaches from compensatory brow elevation, or partial visual field obstruction in more pronounced cases. Apraclonidine 0.5% eye drops temporarily elevate the lid by 1–2 mm through stimulation of Müller’s muscle (King, J Clin Aesthet Dermatol, 2016).
The standard protocol is 1–2 drops of apraclonidine 0.5%, three times daily. Each application provides temporary relief lasting roughly an hour. It does not accelerate recovery. It manages symptoms while the toxin wears off so we should set that expectation clearly.
Lid ptosis typically resolves within 3–4 weeks – faster than brow ptosis because the levator is a smaller muscle with a more localised effect. In our experience, most patients need apraclonidine for 2–3 weeks before improvement becomes self-sustaining.
Two newer pharmacological options are worth knowing about. Brimonidine 0.33% topical gel, applied in a pea-sized amount to the upper eyelid, produced 2 mm of lid elevation in the first reported case of its use for toxin-induced ptosis (Alotaibi et al., JAAD Case Reports, 2022). The evidence is limited to a single case report, but its lower systemic absorption compared with ophthalmic drops makes it an option worth monitoring. Oxymetazoline 0.1% ophthalmic solution (Upneeq) received FDA approval for acquired blepharoptosis in 2020 and works through a direct alpha-adrenergic mechanism on Müller’s muscle. It is not currently available in the UK, but practitioners should be aware of it as the regulatory landscape develops.
Reducing Ptosis Risk in Practice
Technique matters more than product choice. The established clinical guideline is to maintain injection points at least 1–2 cm above the upper eyebrow line, and 2.5–3 cm above the orbital rim (King, 2016; Cavallini et al., Dermatol Surg, 2014). That is the foundation. What else makes a practical difference?
- Assess frontalis dependency before treating. Ask the patient to relax their forehead completely and observe where the brow sits. If it drops significantly, reduce your frontalis dose or consider avoiding it entirely.
- Respect the diffusion halo. Each injection point creates a zone of effect of roughly 1.5 cm at standard dilution. Factor this into placement, particularly near the orbital rim.
- Keep volumes low near the orbit. Higher volume means more diffusion. Use concentrated preparations for glabellar injections in patients with a narrow brow-to-lid distance.
- Individualise your approach. Template injection patterns cause most of the complications I see. The evidence supports tailoring injection points and dosage to individual anatomy – not following a standard map.
These principles are central to what we teach on our hands-on training, where delegates formulate treatment plans and treat real patients under direct 1:1 supervision. If you want to develop your upper face technique in that setting, the Fundamental 5 foundation aesthetics course covers this in depth.
Frequently Asked Questions
How long does ptosis last after anti-wrinkle injections?
Lid ptosis typically resolves within 3–4 weeks; eyebrow ptosis takes approximately 6 weeks. Extended cases lasting up to 13 weeks have been reported but are uncommon. Resolution depends on the dose administered and individual patient metabolism of the toxin (King, JCAD, 2016).
Can apraclonidine treat both eyebrow and lid ptosis?
No. Apraclonidine 0.5% stimulates Müller’s muscle to elevate the upper eyelid by 1–2 mm – it is effective for lid ptosis only. Eyebrow ptosis involves the frontalis, which apraclonidine does not affect. Management of brow ptosis may require a compensatory toxin injection to rebalance the muscles acting on the brow.
What is the incidence rate of ptosis with experienced injectors?
Below 1%. Allergan’s original FDA multicenter study showed 5.4%, but data from experienced practitioners demonstrates significantly lower rates (King, JCAD, 2016). A 2025 UK survey found the gap is closely linked to practitioner qualification – 7.3% of patients treated by mixed-qualification providers reported acute drooping, whereas rates drop well below 1% with properly trained injectors (Smith et al., 2025).
Should you discuss ptosis risk during patient consent?
Without exception. Ptosis is a well-documented complication of upper face anti-wrinkle treatment. Informed consent should cover the possibility of brow heaviness or eyelid drooping, the expected resolution timeline, and available management options. Patients who understand the risks beforehand are far easier to manage if a complication does occur.
Complications are part of clinical practice. What matters is whether you can recognise what has happened anatomically, explain it honestly to the patient, and manage it correctly.
